10.7554/eLife.02523.001 Exchange of extracellular cystine for intracellular glutamate by the
antiporter system x c − is implicated in numerous pathologies. Pharmacological agents that …

Because MYC plays a causal role in many human cancers, including those with hypoxic and
nutrient-poor tumor microenvironments, we have determined the metabolic responses of a …

In the past two decades, several advancements have improved the care of HIV-infected
individuals. Most importantly, the development and deployment of combination antiretroviral …

The metabolic characteristics of tumors present considerable hurdles to immune cell function
and cancer immunotherapy. Using a glutamine antagonist, we metabolically dismantled …

Mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), frequently found in
gliomas and acute myelogenous leukemia, creates a neoenzyme that produces 2-…

Background: Schizophrenia has been hypothesized to be caused by a hypofunction of
glutamatergic neurons. Findings of reduced concentrations of glutamate in the cerebrospinal fluid …

Glutaminase (GLS), which converts glutamine to glutamate, plays a key role in cancer cell
metabolism, growth, and proliferation. GLS is being explored as a cancer therapeutic target, …

Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes
tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine …

We describe here a new strategy for the treatment of stroke, through the inhibition of NAALADase
(N-acetylated-α-linked-acidic dipeptidase), an enzyme responsible for the hydrolysis of …

A series of substituted phosphonate derivatives were designed and synthesized in order to
study the ability of these compounds to inhibit the neuropeptidase N-acetylated α-linked …